ARTICLE | Clinical News
Kynapid vernakalant regulatory update
August 18, 2008 7:00 AM UTC
Astellas received an approvable letter from FDA for Kynapid vernakalant IV to treat atrial fibrillation (AF). The partners said that FDA requested additional data in patients with symptomatic heart fa...